FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 590 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation MOST POPULAR New drug combo for advanced breast cancer approved for NHS in... August 12, 2021 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,... May 19, 2021 ASCO Annual Meeting 2023: Improving Patients’ Lives Through Collaboration, Research, and... May 25, 2023 FDA Approves New Interchangeable Biosimilar to Pertuzumab December 3, 2025 Load more HOT NEWS 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung...
